Hadassah

Hadassah Announces 97 Percent Success Rate with New Hepatitis C Treatment

Monday, Aug 24 2015

The treatment is a combination of Viekarax and Exviera, and was developed by AbbVie, it has now been approved by the Federal Drug Administration and Israel’s Ministry of Health.

“Hepatitis C used to be a death sentence,” reports Prof. Rifaat Safadi, head of the Liver Unit at the Hadassah Medical Organization. He explains, however, that Hadassah has achieved 97 percent success in treating the disease using a new combination of medicines clinically tested at Hadassah and other leading medical centers worldwide.

One of the 100 patients to receive the treatment at Hadassah was Ava Avidar, a mother of three who had undergone a liver transplant. Tragically, she had previously contracted Hepatitis C and the virus which remained in her body attacked her new liver, too. The medicine defeated the virus, however, and she is now doing very well, according to Prof. Safadi. As Mrs. Avidar relates, “It’s nothing short of getting my life back as a gift.”

Now six months post treatment, Mrs. Avidar is free of the virus, has moved to a new home, and returned to her work as a sculptress.

Recalling the journey to health for Mrs. Avidar, Prof. Safadi says: “We began a race against the clock and had to come up with an urgent solution before the new liver failed.” While the new treatment had not yet been approved by Israel’s Ministry of Health, Prof. Safadi believed the medication would save her. Still, his patient could not afford the $100,000 it would cost for the three months of treatment. Fortunately, Mrs. Avidar found the strength to fight her private health insurance company and won her battle, Prof. Safadi relates. 

The treatment, a combination of Viekarax and Exviera, developed by AbbVie, has now been approved by the Federal Drug Administration and Israel’s Ministry of Health, thanks to the success achieved at Hadassah and the other international clinical trials. Prof. Sifadi was also instrumental in getting the new treatment incorporated into Israel’s 2015 health insurance basket, so patients can now receive coverage for this life-saving treatment.

Comments

From: nancy Russo on March 7, 2016
If Gilead is an Isralie drug company how come you didn't use Harvoni?
From: Mary on September 5, 2015
With the medicines for Hep C, do you have anything working for pancreatic cancer?
From: Janet on August 27, 2015
Can you help????
From: Sharon on August 26, 2015
This is Wonderful news! I was a Hep C advocate and patient on the old regimen in 1999 and started a non profit HCV support group. The old meds were very hard on the body with many side effects & after 1 year on this I have been viral free for 15 yrs! Thank You Hadassah Hospital for your continued research to improve the cure rate for this horrific liver disease that millions have and may not even know. Keep up All your Wonderful Work!
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Tuesday, Aug 14 2018

Hadassah Hospital Helps Educate Mikvah Attendants To Bolster Women’s Health

After a woman emerges from the ritual bath (mikveh) and wraps herself in a towel, says mikveh attendant Daniella Salomon, “I keep an eye out” for anything unusual.

READ MORE ›
alt_text

Tuesday, Aug 7 2018

American Medical Attaché and Consulate Nurse Tour Hadassah Hospital Ein Kerem

Jennifer Kmiecinski, Medical Attaché to the Consulate General of the United States in Israel, visited Hadassah Hospital Ein Kerem earlier this month to assess the level of health care available to American personnel serving in Israel.

READ MORE ›
alt_text

Thursday, Aug 2 2018

Thyroid Cancer Diagnosis Enhanced at Hadassah Using Advanced Gene Sequencing

Hadassah Medical Organization researchers, using next generation sequencing (NGS), have identified a highly accurate RNA panel that distinguishes thyroid cancer from benign nodules.

READ MORE ›
alt_text

Thursday, Aug 2 2018

Two Hadassah Ophthalmology Articles Are Among Top 100 Most Cited in Four Decades

Two articles by Hadassah Medical Organization ophthalmologists are among the 100 most cited ophthalmology articles from 1975-2017. One is ranked 11th.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More